AKT1 and hepatocellular carcinoma: The cells harboring HCC-derived EGFR mutants are erlotinib-resistant, as erlotinib up to high concentration could only induce partial inhibition of EGFR phosphorylation, and partial or no inhibition of AKT and ERK phosphorylation, and partial induction of apoptosis and autophagy.